



ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

esmo.org

PERSONALIZED MEDICINE SYMPOSIUM

**Targeting the HER/EGFR
family in breast, lung
and colorectal cancers**

**SIGNALLING
PATHWAYS IN CANCER**
Programme Book

andor-group.com

Sitges-Barcelona, Spain

1-2 March 2013

**THE BEST ONCOLOGISTS
ARE MEETING SOON**

**MAY WE
INTRODUCE YOU?**

Excellence in cancer treatment is a shared goal: we can all provide better care when we exchange expertise and knowledge. ESMO's regular congresses, multidisciplinary meetings, and topic-specific events keep you in the loop, sharing the latest information and making new contacts.



MARK YOUR CALENDAR!

2-4 May 2013, Brussels, Belgium

Translational Research in Breast Cancer - 5th IMPAKT edition

9-11 May 2013, Lugano, Switzerland

European Multidisciplinary Conference in Thoracic Oncology - EMCTO

27 September - 1 October 2013, Amsterdam, Netherlands

European Cancer Congress - 17th ECCO - 38th ESMO - 32nd ESTRO

For more information please visit **esmo.org/conferences**

SYMPOSIUM INTRODUCTION

On behalf of the European Society for Medical Oncology (ESMO) it gives us great pleasure to welcome you to the first series of symposia on personalized medicine, the ESMO Symposium on Signalling Pathways in Cancer.

The HER membrane receptors are a logical point to start the series from the biological perspective, due to its clinical relevance for medical oncologists. We are pleased to have brought together academic, clinical and industry researchers working in these tumour settings to share knowledge through interactive sessions and workshops.

We trust participants will benefit from this attractive programme comprising of plenary sessions on the principles of signalling transduction, mechanisms of primary and secondary resistance to targeted therapies, preclinical models and biomarkers, with parallel sessions on dysregulation of HER receptors and potential targeting strategies in breast, lung and colorectal cancers.

Leading clinical researchers in the field will present a synthesis of the presentations, address the complexity of the current challenges and provide perspectives on areas for future innovation and collaboration. We highly recommend you to attend the round table discussion on the final day that will gather both academic, clinical and industry leaders.

A sincere thank you to the Scientific Committee, invited speakers, organizers and sponsors for their commitment to this symposium on personalized medicine. We hope that you enjoy the meeting enough to join us again for the next symposium of the personalized medicine series.



Fortunato Ciardiello
Naples, Italy
Co-chair



Josep Taberno
Barcelona, Spain
Co-chair

ABOUT ESMO

European Society for Medical Oncology (ESMO)
Via Luigi Taddei 4, 6962 Viganello
Switzerland

T +41 (0)91 973 19 00

F +41 (0)91 973 19 02

esmo.org

ESMO is the leading non-profit, European professional organization, committed to advancing the specialty of medical oncology and promoting a multidisciplinary approach to cancer treatment and care.

Since 1975 ESMO's mission has been to advance cancer care and cure. We achieve this through fostering and disseminating good science that leads to better medicine and determines best practice. The ESMO community is a powerful alliance of more than 7,000 committed oncology professionals from over 120 countries. As a trusted organization with 35 years of experience and over 500 expert committee members, ESMO serves its members and the oncology community.

SYMPOSIUM ORGANIZATION

ESMO

ESMO Head Office
Via Luigi Taddei 4
6962 Viganello-Lugano
Switzerland

Tel. +41 (0)91 973 19 94
Fax +41 (0)91 973 19 18
symposia@esmo.org
esmo.org

Venue

Meliá Sitges
Joan Salvat Paapasseit, 38
08870 Sitges, Barcelona
Spain

Tel. +34 93 811 67 09
Fax +34 93 894 95 08
camila.devita@melia.com
www.melia.com/hotels/spain/sitges/melia-sitges

SYMPOSIUM OFFICERS

Chairs

Fortunato Ciardiello, Naples, Italy

Josep Taberner, Barcelona, Spain

Scientific Committee

Jean-Yves Douillard, St. Herblain, France

Andrés Cervantes, Valencia, Spain

Martine Piccart, Brussels, Belgium

Cristiana Sessa, Bellinzona, Switzerland

Rolf A. Stahel, Zurich, Switzerland

Eric Van Cutsem, Leuven, Belgium

ACKNOWLEDGMENTS

ESMO wishes to express its gratitude to companies supporting the first ESMO Symposium on Signalling Pathways in Cancer.

Platinum Sponsor



Silver Sponsor



Merck Serono is a
division of Merck



Product promotion at ESMO events

Advertising of a specific product does not mean acceptance by ESMO, and it is the full responsibility of the corporation that it is in accordance with the Swiss, Spanish and European law, where applicable. ESMO accepts no responsibility for misprints.

GENERAL INFORMATION

Symposium venue

The event will be held at the Hotel Meliá Sitges, located 30 minutes away from Barcelona International airport.

Official language

The official language of the Symposium is English. Sessions will not be translated.

Participation

About 150 specialists in breast, lung and colorectal cancers are expected to join the Symposium.

CME accreditation

The ESMO Symposium on Signalling Pathways in Cancer scientific programme has been designated for a maximum of 8 hours of European CME credits (ECMEC's).

ACOE works in conjunction with the European Accreditation Council for Continuing Medical Education (EACCME) operating under the umbrella of the European Union of Medical Specialists (UEMS). The EACCME plays the role of a clearinghouse, facilitating the accreditation endorsement by the national CME regulatory bodies.

CME credits gained by your participation in the ESMO Symposium on Signalling Pathways in Cancer are recognised by most of the national CME authorities in Europe, which have agreed to cooperate in this European system.

Through a mutual agreement between the UEMS and the American Medical Association (AMA), the European CME credits are also recognised towards the Physician's Recognition Award (PRA). To convert European CME credits to AMA PRA Category 1 credits, contact AMA (www.ama-assn.org).

The Symposium has also been accredited with 11 ESMO-MORA category 1 points.

In the world of oncology
Combination is key

Merck Serono Oncology
combines approaches that target



Tumor cell
Tumor environment
Immune system

to optimize therapeutic success



Merck Serono Oncology | *Combination is key*™

Merck Serono

MERCK

Certificate of Attendance

All participants are entitled to request a Certificate of Attendance at the on-site registration desk. The Certificate will be available for collection in return for the completed evaluation form, from Saturday morning 2 March.

The Certificate of Attendance will indicate the maximum number of credit points (1 credit point per 1 hour of programme attended up to a maximum of 3 credits per half day) related to the Symposium. However, it is the participant's responsibility to complete the Certificate of Attendance with the number of hours of scientific programme (= number of credit points) that he/she has actually attended.

OncologyPRO

Access to the highest quality scientific knowledge at a click. In addition to a wider range of scientific information and news services, OncologyPRO provides access to materials developed by ESMO. Webcasts and reports from the Symposium will be available at <http://oncologypro.esmo.org/> ESMO designed OncologyPRO in partnership with Thomson Reuters specifically to foster the sharing of knowledge and best practice for both clinical practice and research. OncologyPRO offers ESMO members an unparalleled resource - integrating regularly updated oncology news, clinical research, biomarker and drug databases, practice guidelines and tools, clinical trial information, abstracts from more than 110 oncology-relevant journals and more, in a simple, searchable platform.

Symposium Webcast

The webcast of the Symposium will include all the sessions of the official programme, where speaker permission is granted, and will be made available within 48 hours on:

- OncologyPRO for ESMO members
- The Symposium Website for all delegates for 3 months after the Symposium.

Important: keep your badge as you will be requested to enter your badge ID code and last name to log in.

Internet WiFi access

Symposium delegates will receive a free ticket onsite with username and password to connect to the basic WiFi.

NOT YET A USER?

**TRY ONCOLOGY » PRO,
THE SCIENTIFIC AND
EDUCATIONAL PORTAL**



NEW IN ONCOLOGYPRO!

» ESMO GLOSSARY IN MOLECULAR BIOLOGY OF CANCER


Find out more at the ESMO stand.



POWERED BY
THOMSON REUTERS

Visit us at oncologypro.esmo.org

Major sponsors

 astellas ONCOLOGY <small>Changing Tomorrow in Cancer Care</small>	 Bristol-Myers Squibb	 MSD
Lilly Oncology Making science personal. <i>Lilly</i>	janssen <small>PHARMACEUTICAL COMPANY of Johnson & Johnson</small>	Pfizer Oncology

Main sponsors

AMGEN	AstraZeneca	Novartis <small>Novartis HealthCare</small>
Boehringer Ingelheim	Genomic Health	Pharma Mar <small>Grupo Janssen</small>
		Roche

ESMO membership and other activities

For matters regarding ESMO membership and other ESMO activities, participants are cordially invited to visit the ESMO booth in the display area.

Insurance

The organizers bear no responsibility for untoward events in connection with, before, during and after the Symposium.

Passport / visa

A valid identity card is sufficient for entry into Spain for citizens of EU member countries.

Speaker Preview Centre

Speakers should deliver and check their presentation at the Speakers Preview Centre located in the “Mestral 1” room on level -1 no later than 3 hours before the start of their session. For the first sessions of the day, presentations can be delivered from 11:00. Speakers are kindly asked to keep their presentation within the given time limits, including discussion time.

Speaker Preview Centre opening hours

Friday, 1 March	11:00-18:00
Saturday, 2 March	08:00-15:30

Badge

The badge is the only official evidence of registration, thus, participants not wearing their badge do not have access to the Symposium. Loss of badge is loss of registration and a new badge will be issued only upon payment of the pro-rata fee.

Registration desk opening hours

Friday, 1 March	12:00-18:00
Saturday, 2 March	08:00-16:00

Full registration fees

The registration fee includes access to the Symposium, Symposium material, the ESMO Glossary in molecular biology of cancer, welcome reception, lunch on Saturday, coffee breaks and VAT.

Early registration, until 11 January 2013

Non ESMO member fee	EUR 200
---------------------	---------

ESMO Member fee	EUR 100
-----------------	---------

Junior ESMO Member fee	EUR 50
------------------------	--------

Late registration, until 13 February 2013

Non ESMO member fee	EUR 250
---------------------	---------

ESMO member fee	EUR 150
-----------------	---------

Junior ESMO Member fee	EUR 50
------------------------	--------

Full registration, from 14 February 2013

Non ESMO member fee	EUR 300
---------------------	---------

ESMO member fee	EUR 300
-----------------	---------

Junior ESMO Member fee	EUR 50
------------------------	--------

Industry display area opening hours

Friday, 1 March	14:00-19:00
-----------------	-------------

Saturday, 2 March	09:30-15:30
-------------------	-------------

Filming, Recording and Photography

Symposium content is copyright of ESMO. It is strictly forbidden to record or capture in any way the Symposium programme and display area.

No-smoking policy

The ESMO Symposium on Signalling Pathways in Cancer and the concomitant display area have been designated as non-smoking events throughout the entire venue, including all meeting rooms, functions, registration and catering areas. All delegates are kindly required to respect the no-smoking policy.

SYMPOSIUM PROGRAMME

Friday, 1 March 2013

14:00/ Introduction

14:20

Chairs: Fortunato Ciardiello, Naples, Italy
and Josep Taberero, Barcelona, Spain

14:00

ESMO Educational activities: From past to future.
Focus on personalized medicine
Jean-Yves Douillard, St. Herblain, France

MODULE 1: PRINCIPLES OF TARGETED THERAPY

14:20/ The basis of targeted therapy

15:20

Chair: Fortunato Ciardiello, Naples, Italy

14:20

The principles of signal transduction
Yosef Yarden, Rehovot, Israel

14:50

Mechanisms of primary and secondary resistance
Giampaolo Tortora, Verona, Italy

15:20/ Pre-clinical models

16:00

Chair: Josep Taberero, Barcelona, Spain

15:20

Conventional preclinical models
Joaquín Arribas, Barcelona, Spain

15:40

Tumour patient derived models
Livio Trusolino, Candiolo, Italy

16:00

Coffee break

16:20/ Dissecting the field of biomarkers

18:00

Chair: Fortunato Ciardiello, Naples, Italy

16:20

Large scale datasets: Picking-up the complexity
Emile E. Voest, Utrecht, Netherlands

16:40

Lively biomarkers: Opportunities for the liquid biopsy
Alberto Bardelli, Candiolo, Italy

17:00

Characterization of one disease in different subtypes
Aleix Prat, Barcelona, Spain

17:20

Pitfalls and challenges with tumour tissue specimens
Federico Rojo, Madrid, Spain

17:40

Tumour-host interaction: Focus on immune response
and microenvironment
Giuseppe Curigliano, Milan, Italy

18:00

Welcome reception

Saturday, 2 March 2013

08:30/ **Clinical pharmacology concepts of targeted therapy**

09:20 Chair: Josep Tabernero, Barcelona, Spain

08:30 Pharmacology basis of targeted therapy
Fortunato Ciardiello, Naples, Italy

09:00 How to maximize smart clinical development from phase I
Cristiana Sessa, Bellinzona, Switzerland

09:20/ **Guidelines**

09:40 Chair: Fortunato Ciardiello, Naples, Italy

09:20 ESMO Guidelines: How deep we go in personalized medicine
Andrés Cervantes, Valencia, Spain

09:40 Coffee break

MODULE 2: EGFR/HER FAMILY TARGETED THERAPY IN BREAST, COLORECTAL AND LUNG CANCER (PARALLEL SESSIONS)

10:00/ **Breast cancer**

12:20 Chair: Martine Piccart, Brussels, Belgium

10:00 Characterization of HER-2/neu breast cancer
Monica Arnedos, Villejuif, France

10:30 The hallmark of trastuzumab in the treatment of breast cancer
Fatima Cardoso, Lisbon, Portugal

11:00 Is there a role for personalization between trastuzumab
and lapatinib?
Christoph Zielinski, Vienna, Austria

11:20 Adjuvant and neoadjuvant strategies in HER-2/neu disease
Luca Gianni, Milan, Italy

11:50 The landscape of new anti-HER-2/neu treatments
Martine Piccart, Brussels, Belgium

10:00/ **Colorectal cancer**

12:20 Chair: Eric Van Cutsem, Leuven, Belgium

10:00 Signatures of EGFR dependence: Are we there yet?
Gabriel Capellà, Barcelona, Spain

10:20 Clinical evidence of EGFR inhibition in metastatic
colorectal cancer
Eric Van Cutsem, Leuven, Belgium

10:50 Predictive biomarkers of EGFR inhibition: What is there
beyond KRAS?
Salvatore Siena, Milan, Italy

11:10 On-treatment biomarkers of EGFR inhibition
Dirk Arnold, Freiburg, Germany

- 11:30 Mechanisms of secondary resistance to EGFR inhibition: Role for EGFR inhibition re-challenge
Andrea Sartore-Bianchi, Milan, Italy
- 11:50 New opportunities for EGFR-pathway inhibition
Josep Tabernero, Barcelona, Spain
-

**10:00/
12.20 Lung cancer**
Chair: Rolf A. Stahel, Zurich, Switzerland

- 10:00 Current characterization of lung cancer
Enriqueta Felip, Barcelona, Spain
- 10:30 First generation EGFR inhibitors: The breakthrough in stratified medicine in lung cancer
Benjamin Besse, Villejuif, France
- 11:00 New EGFR inhibitors: The cutting-edge frontier
Rolf A. Stahel, Zurich, Switzerland
- 11:15 HER2/neu in non-small cell lung cancer
Solange Peters, Lausanne, Switzerland
- 11:30 Mechanisms of primary/secondary resistance to EGFR inhibitors
Silvia Novello, Orbassano-Turin, Italy
- 11:50 Building on EGFR inhibition: Synthetic lethality strategies
Rafael Rosell, Badalona, Spain
-

12:20 Lunch

**13:30/
15:30 MODULE 3: CONFRONTING THE COMPLEXITY OF
CANCER THROUGH COLLABORATIVE INNOVATION
BETWEEN ACADEMIA AND PHARMA**
Chairs: Fortunato Ciardiello, Naples, Italy and
Josep Tabernero, Barcelona, Spain

- 13:30 Key take-home messages from the Breast cancer session
Martine Piccart, Brussels, Belgium
- 13:50 Key take-home messages from the Colorectal cancer session
Eric Van Cutsem, Leuven, Belgium
- 14:10 Key take-home messages from the Lung cancer session
Rolf A. Stahel, Zurich, Switzerland
- 14:30 Round-table discussion between Academia and Pharma,
moderated by Tim Maughan, Oxford, UK
- 15:30 Adjourn
-

5 GOOD REASONS TO JOIN ESMO:

- Access to OncologyPRO
- Subscription to Annals of Oncology
- Reduced registration fees to ESMO congresses
- Access to ESMO educational and scientific material
- Subscription to e-News and networking opportunities



**Become an
ESMO member**

**JOIN THE REFERENCE
SOCIETY FOR MEDICAL
ONCOLOGISTS**

INVITED SPEAKER DISCLOSURES

Arnedos Monica	The author has declared no conflict of interest
Arnold Dirk	Research Support: Merck Serono. Speaker honoraria: Amgen, Merck Serono
Arribas Joaquin	The author has declared no conflict of interest
Bardelli Alberto	Shareholder Horizon Discovery
Besse Benjamin	Research grants from Roche, AstraZeneca, Boehringer Ingelheim and Pfizer
Capellà Gabriel	Has conducted and is conducting research in collaboration with Agendia
Cardoso Fatima	Honorarium, consultancy, speaker bureau: Roche and GSK
Cervantes Andrés	The author has declared no conflict of interest
Ciardello Fortunato	Scientific advisory boards and satellite symposia speaker: Bayer, Merck. Research funding: Bayer, Merck Serono
Curigliano Giuseppe	Has any financial interest in, or arrangement with, a company whose products or services are discussed in the lecture
Douillard Jean-Yves	Compensated advisory board and lectures in sym- posia: Amgen, Merck Serono, Roche, Boehringer Ingelheim, Pfizer, GSK and Sanofi-Aventis. Research contract: Merck Serono
Felip Enriqueta	The author has declared no conflict of interest
Gianni Luca	The author has declared no conflict of interest
Maughan Tim	The author has declared no conflict of interest
Novello Silvia	The author has declared no conflict of interest
Peters Solange	The author has declared no conflict of interest
Piccart Martine	Consultancy: Sanofi-Aventis, Amgen, Bayer, Roche-Genentech, PharmaMar, AstraZeneca. Honoraria: Sanofi-Aventis, Amgen, Novartis, Roche-Genentech, PharmaMar, AstraZeneca

Prat Aleix	The author has declared no conflict of interest
Rojo Federico	The author has declared no conflict of interest
Rosell Rafael	The author has declared no conflict of interest
Sartore-Bianchi Andrea	Received payment for board membership from Amgen and for lectures from Amgen, Roche and Merck Serono
Sessa Cristiana	The author has declared no conflict of interest
Siena Salvatore	Is a clinical investigator or advisory board member of Amgen, ArQule, AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Genentech, Genomic Health, GSK, Merck Serono, Merrimack, Pfizer, Nerviano Medical Science, Roche and Sanofi-Aventis
Stahel Rolf A.	Advisory board for AstraZeneca, Boehringer Ingelheim and Roche
Taberero Josep	Consultant / Advisory role: Amgen, BMS, Genentech, Merck KGaA, Millennium, Novartis, Onyx, Pfizer, Roche and Sanofi. Honoraria Amgen, Merck KGaA, Novartis, Roche and Sanofi
Tortora Giampaolo	The author has declared no conflict of interest
Trusolino Livio	Receives research grants from Symphogen and Merck Serono to test lead compounds in patient-derived colorectal cancer xenografts
Van Cutsem Eric	Research funding to University of Leuven: Amgen, Bayer, Merck, Novartis, Roche and Sanofi
Voest Emile E.	The author has declared no conflict of interest
Yarden Yosef	The author has declared no conflict of interest
Zielinski Christoph	Honoraria from Roche.

SPONSOR PROFILES

Amgen (Europe) GmbH

Display no. 3

Dammstrasse 23
6300 Zug
Switzerland

Tel: +41 41 3690 300
Fax: +41 41 3690 400

www.AmgenOncology-International.com

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

Astellas Pharma Europe Ltd.

Display no. 2

2000 Hillswood Drive
Chertsey, Surrey KT16 0RS
United Kingdom

Tel: +44 203 379 8000
Fax: +44 203 379 8001

www.astellas.eu

Astellas is already an established player in the fields of Transplantation, Urology, Dermatology, Anti-Infectives and Pain Management. We are now bringing our expertise to the field of Oncology. With no fewer than 12 separate therapies currently under clinical development, we aim to fulfil not just our potential, but our promise to change tomorrow for patients suffering with conditions such as prostate cancer, advanced renal cell carcinoma and haematological malignancies. With our dynamic partners and our focus on innovative solutions, Astellas is advancing research and development of a robust portfolio of oncology therapeutics targeting fundamental aspects of cancer biology and supportive care.

Merck Serono - Merck KGaA

Display no. 1

Frankfurter Str. 250
64293 Darmstadt
Germany

Tel: +49 6151 72-0
Fax: +49 6151 72-2000

www.merck.de

Merck licensed the right to market Erbitux outside the US and Canada from ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, in 1998. In Japan, ImClone, Bristol-Myers Squibb Company and Merck jointly develop and commercialize Erbitux. Merck acquired the exclusive worldwide rights for development and commercialization of L-BLP25 from Oncothyreon Inc. in 2007. In Japan, Merck entered into a co-development and co-marketing agreement for L-BLP25 with Ono Pharmaceutical. Merck signed a license and co-development agreement for TH-302 with Threshold Pharmaceuticals Inc. in 2012.

Changing tomorrow



Astellas has made a commitment to change tomorrow – a commitment that we are bringing to the field of oncology. We aim to create innovative treatments that will genuinely improve the lives of cancer patients. To do this we are focusing our R&D and partnership efforts into precision medicine that will create first-in-class or best-in-class programmes. This has resulted in no fewer than 12 separate therapies under clinical development into conditions including prostate cancer, other solid tumours like pancreatic cancer, breast cancer and advanced renal cell carcinoma, as well as haematological malignancies.

These are the challenges we have set ourselves because CHANGING TOMORROW is more than just words – it is what we must do to give cancer patients real hope of a tomorrow worth looking forward to.

ONCOLOGY
TRANSPLANTATION
UROLOGY
DERMATOLOGY
ANTI-INFECTIVES
PAIN MANAGEMENT



astellas
Leading Light for Life

www.astellas.eu

© December 2011 Astellas Pharma Europe Ltd. CSC0461

ASTELLAS, Leading Light for Life, the Star logo, CHANGING TOMORROW and the Ribbon logos are trade marksof Astellas Pharma Inc. and/or its related entities.